{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:50:32Z","timestamp":1791312632277,"version":"4.3.1"},"reference-count":159,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1124\/molpharm.121.000460","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T08:40:12Z","timestamp":1646383212000},"page":"275-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia"],"prefix":"10.1016","volume":"101","author":[{"given":"Shalini","family":"Dogra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Jeffrey","family":"Conn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/molpharm.121.000460_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-244X-13-143","article-title":"A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia","volume":"13","author":"Adams","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1152\/jn.00532.2019","article-title":"Alterations in sleep, sleep spindle, and EEG power in mGluR5 knockout mice","volume":"123","author":"Aguilar","year":"2020","journal-title":"J Neurophysiol"},{"key":"10.1124\/molpharm.121.000460_bib3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1999.tb11321.x","article-title":"Activation of N-methyl-D-aspartate receptors reverses desensitization of metabotropic glutamate receptor, mGluR5, in native and recombinant systems","volume":"868","author":"Alagarsamy","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/molpharm.121.000460_bib4","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/npp.2009.30","article-title":"mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning","volume":"34","author":"Ayala","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.121.000460_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032849","article-title":"Deleterious GRM1 mutations in schizophrenia","volume":"7","author":"Ayoub","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.121.000460_bib6","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/npp.2016.2","article-title":"An mGlu5-positive allosteric modulator rescues the neuroplasticity deficits in a genetic model of NMDA receptor hypofunction in schizophrenia","volume":"41","author":"Balu","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.121.000460_bib7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/schbul\/sbx065","article-title":"Preclinical models to investigate mechanisms of negative symptoms in schizophrenia","volume":"43","author":"Barnes","year":"2017","journal-title":"Schizophr Bull"},{"key":"10.1124\/molpharm.121.000460_bib8","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1021\/jm400650w","article-title":"Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor","volume":"56","author":"Bartolom\u00e9-Nebreda","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/molpharm.121.000460_bib9","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1111\/jnc.15333","article-title":"Mice deficient in the NAAG synthetase II gene Rimkla are impaired in a novel object recognition task","volume":"157","author":"Becker","year":"2021","journal-title":"J Neurochem"},{"key":"10.1124\/molpharm.121.000460_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nn.2447","article-title":"Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes","volume":"13","author":"Belforte","year":"2010","journal-title":"Nat Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/mol.107.035170","article-title":"A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis","volume":"72","author":"Benneyworth","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib12","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.1523\/JNEUROSCI.22-22-09679.2002","article-title":"Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes","volume":"22","author":"Benquet","year":"2002","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.schres.2005.04.001","article-title":"Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment","volume":"77","author":"Bishop","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1124\/molpharm.121.000460_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hup.1163","article-title":"Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia","volume":"26","author":"Bishop","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"10.1124\/molpharm.121.000460_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-014-3649-4","article-title":"Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia","volume":"232","author":"Bishop","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1101\/lm.777308","article-title":"Impaired discrimination learning in mice lacking the NMDA receptor NR2A subunit","volume":"15","author":"Brigman","year":"2008","journal-title":"Learn Mem"},{"key":"10.1124\/molpharm.121.000460_bib17","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1111\/j.1460-9568.2003.03073.x","article-title":"Disruption of prepulse inhibition in mice lacking mGluR1","volume":"18","author":"Brody","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00213-003-1635-3","article-title":"Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice","volume":"172","author":"Brody","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.mp.4001404","article-title":"Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors","volume":"9","author":"Brody","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF03033300","article-title":"Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice","volume":"6","author":"Brody","year":"2004","journal-title":"Neurotox Res"},{"key":"10.1124\/molpharm.121.000460_bib21","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/npp.2015.44","article-title":"Environmental enrichment ameliorates behavioral impairments modeling schizophrenia in mice lacking metabotropic glutamate receptor 5","volume":"40","author":"Burrows","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.121.000460_bib22","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1523\/JNEUROSCI.1497-06.2006","article-title":"Concomitant deficits in working memory and fear extinction are functionally dissociated from reduced anxiety in metabotropic glutamate receptor 7-deficient mice","volume":"26","author":"Callaerts-Vegh","year":"2006","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00213-004-1827-5","article-title":"The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats","volume":"175","author":"Campbell","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib24","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1124\/mol.110.067488","volume":"79","author":"Caraci","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.psychres.2015.06.012","article-title":"Evaluation of relationship between GRM3 polymorphisms and cognitive function in schizophrenia of Han Chinese","volume":"229","author":"Chang","year":"2015","journal-title":"Psychiatry Res"},{"key":"10.1124\/molpharm.121.000460_bib26","article-title":"A polymorphism in the glutamate metabotropic receptor 7 is associated with cognitive deficits in the early phases of psychosis","author":"Chaumette","year":"2020","journal-title":"Schizophr Res."},{"key":"10.1124\/molpharm.121.000460_bib27","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1021\/cb500560h","article-title":"Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics","volume":"9","author":"Cho","year":"2014","journal-title":"ACS Chem Biol"},{"key":"10.1124\/molpharm.121.000460_bib28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fnmol.2018.00316","article-title":"Negative allosteric modulators of mGlu7 receptor as putative antipsychotic drugs","volume":"11","author":"Cie\u015blik","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib29","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1007\/s00213-018-4980-y","article-title":"Mutual activation of glutamatergic mGlu4 and muscarinic M4 receptors reverses schizophrenia-related changes in rodents","volume":"235","author":"Cie\u015blik","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib30","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/sj.bjp.0705861","article-title":"Interactions between NMDA receptors and mGlu5 receptors expressed in HEK293 cells","volume":"142","author":"Collett","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell Mol Neurobiol"},{"key":"10.1124\/molpharm.121.000460_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuropharm.2014.08.010","article-title":"The role of group II metabotropic glutamate receptors in cognition and anxiety: comparative studies in GRM2(-\/-), GRM3(-\/-) and GRM2\/3(-\/-) knockout mice","volume":"89","author":"De Filippis","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.121.000460_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/sj.mp.4000848","article-title":"The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia","volume":"6","author":"Devon","year":"2001","journal-title":"Mol Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2017.10.026","article-title":"Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system","volume":"128","author":"Di Menna","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.121.000460_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108687","article-title":"Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders","volume":"196","author":"Dogra","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.121.000460_bib36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.biopsych.2021.02.970","article-title":"Activating mGlu3 metabotropic glutamate receptors rescues schizophrenia-like cognitive deficits through metaplastic adaptations within the hippocampus","volume":"90","author":"Dogra","year":"2021","journal-title":"Biol Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbr.2004.01.008","article-title":"Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function","volume":"153","author":"Duncan","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1124\/molpharm.121.000460_bib38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1460-9568.2005.04210.x","article-title":"Increased measures of anxiety and weight gain in mice lacking the group III metabotropic glutamate receptor mGluR8","volume":"22","author":"Duvoisin","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib39","doi-asserted-by":"crossref","first-page":"12604","DOI":"10.1073\/pnas.0405077101","article-title":"Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia","volume":"101","author":"Egan","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.121.000460_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1601-183X.2009.00532.x","article-title":"The effect of mGlu8 deficiency in animal models of psychiatric diseases","volume":"9","author":"Fendt","year":"2010","journal-title":"Genes Brain Behav"},{"key":"10.1124\/molpharm.121.000460_bib41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/tpj.2009.24","article-title":"Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia","volume":"9","author":"Fijal","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/molpharm.121.000460_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/gbb.12654","article-title":"Phenotypic profiling of mGlu7 knockout mice reveals new implications for neurodevelopmental disorders","volume":"19","author":"Fisher","year":"2020","journal-title":"Genes Brain Behav"},{"key":"10.1124\/molpharm.121.000460_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019011","article-title":"Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder","volume":"6","author":"Frank","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.121.000460_bib44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01.ypg.0000056682.82896.b0","article-title":"Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia","volume":"13","author":"Fujii","year":"2003","journal-title":"Psychiatr Genet"},{"key":"10.1124\/molpharm.121.000460_bib45","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.105.091074","article-title":"A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2\/3 receptor agonist in mouse models predictive of antipsychotic activity","volume":"315","author":"Galici","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.106.102046","article-title":"Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice","volume":"318","author":"Galici","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib47","doi-asserted-by":"crossref","first-page":"7959","DOI":"10.1021\/acs.jmedchem.5b00727","volume":"58","author":"Garcia-Barrantes","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/molpharm.121.000460_bib48","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/npp.2011.298","article-title":"Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator","volume":"37","author":"Gastambide","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.121.000460_bib49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0028-3908(02)00078-3","article-title":"Performance deficits of mGluR8 knockout mice in learning tasks: the effects of null mutation and the background genotype","volume":"43","author":"Gerlai","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.121.000460_bib50","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0893-133X(00)00136-6","article-title":"Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors","volume":"23","author":"Gewirtz","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.121.000460_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv053","article-title":"Functional dissociation of group III metabotropic glutamate receptors revealed by direct comparison between the behavioral profiles of knockout mouse lines","volume":"18","author":"Goddyn","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/molpharm.121.000460_bib52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nlm.2008.01.001","article-title":"Deficits in acquisition and extinction of conditioned responses in mGluR7 knockout mice","volume":"90","author":"Goddyn","year":"2008","journal-title":"Neurobiol Learn Mem"},{"key":"10.1124\/molpharm.121.000460_bib53","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1176\/appi.ajp.158.9.1367","article-title":"The emerging role of glutamate in the pathophysiology and treatment of schizophrenia","volume":"158","author":"Goff","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Gonz\u00e1lez-Maeso","year":"2008","journal-title":"Nature"},{"key":"10.1124\/molpharm.121.000460_bib55","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1016\/j.bmcl.2005.06.017","article-title":"Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia","volume":"15","author":"Govek","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/molpharm.121.000460_bib56","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/jpet.113.206623","article-title":"N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement","volume":"347","author":"Gregory","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib57","doi-asserted-by":"crossref","first-page":"35320","DOI":"10.1038\/srep35320","article-title":"The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia","volume":"6","author":"Griebel","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/molpharm.121.000460_bib58","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0028-3908(02)00332-5","article-title":"The mGluR5 antagonist MPEP, but not the mGluR2\/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity","volume":"43","author":"Henry","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.121.000460_bib59","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jphs.2015.02.004","article-title":"Antipsychotic profiles of TASP0443294, a novel and orally active positive allosteric modulator of metabotropic glutamate 2 receptor","volume":"127","author":"Hikichi","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/molpharm.121.000460_bib60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1254\/jphs.13036FP","article-title":"Stimulation of metabotropic glutamate (mGlu) 2 receptor and blockade of mGlu1 receptor improve social memory impairment elicited by MK-801 in rats","volume":"122","author":"Hikichi","year":"2013","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/molpharm.121.000460_bib61","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2009.08.047","article-title":"Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in rodents","volume":"639","author":"Hikichi","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib62","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.114.218651","article-title":"Neurophysiologic and antipsychotic profiles of TASP0433864, a novel positive allosteric modulator of metabotropic glutamate 2 receptor","volume":"351","author":"Hiyoshi","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbr.2004.03.015","article-title":"Lack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memory","volume":"154","author":"H\u00f6lscher","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1124\/molpharm.121.000460_bib64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.12547","article-title":"The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies","volume":"1338","author":"Hu","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/molpharm.121.000460_bib65","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1016\/j.bmcl.2016.07.065","article-title":"Oxazolidinone-based allosteric modulators of mGluR5: defining molecular switches to create a pharmacological tool box","volume":"26","author":"Huang","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/molpharm.121.000460_bib66","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0269881121991569","article-title":"Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: an in vivo electrophysiology study in male mice","volume":"35","author":"Inserra","year":"2021","journal-title":"J Psychopharmacol"},{"key":"10.1124\/molpharm.121.000460_bib67","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1113\/jphysiol.1997.sp022030","article-title":"Synapse-selective impairment of NMDA receptor functions in mice lacking NMDA receptor epsilon 1 or epsilon 2 subunit","volume":"500","author":"Ito","year":"1997","journal-title":"J Physiol"},{"key":"10.1124\/molpharm.121.000460_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070415","article-title":"mGluR5 ablation in cortical glutamatergic neurons increases novelty-induced locomotion","volume":"8","author":"Jew","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/molpharm.121.000460_bib69","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1101\/lm.5.4.331","article-title":"Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5","volume":"5","author":"Jia","year":"1998","journal-title":"Learn Mem"},{"key":"10.1124\/molpharm.121.000460_bib70","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/cercor\/bhx005","article-title":"mGluR2 versus mGluR3 metabotropic glutamate receptors in primate dorsolateral prefrontal cortex: postsynaptic mGluR3 strengthen working memory networks","volume":"28","author":"Jin","year":"2018","journal-title":"Cereb Cortex"},{"key":"10.1124\/molpharm.121.000460_bib71","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s41380-017-0015-z","article-title":"Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function","volume":"24","author":"Joffe","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib72","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1021\/jm034015u","article-title":"Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine","volume":"46","author":"Johnson","year":"2003","journal-title":"J Med Chem"},{"key":"10.1124\/molpharm.121.000460_bib73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00213-004-2099-9","article-title":"Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)","volume":"179","author":"Johnson","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib74","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1124\/jpet.114.214437","article-title":"Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders","volume":"350","author":"Kalinichev","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib75","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1124\/jpet.112.200915","article-title":"ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization","volume":"344","author":"Kalinichev","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib76","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/cercor\/bhu017","article-title":"GluN2A-\/- mice lack bidirectional synaptic plasticity in the dentate gyrus and perform poorly on spatial pattern separation tasks","volume":"25","author":"Kannangara","year":"2015","journal-title":"Cereb Cortex"},{"key":"10.1124\/molpharm.121.000460_bib77","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41386-020-0706-z","article-title":"Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers","volume":"45","author":"Kantrowitz","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.121.000460_bib78","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.06.002","article-title":"Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia","volume":"66","author":"Kinon","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.121.000460_bib79","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib80","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/molpharm.121.000460_bib81","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.npp.1301133","article-title":"The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats","volume":"32","author":"Koros","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.121.000460_bib82","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-004-1982-8","article-title":"Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects","volume":"179","author":"Krystal","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib83","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00213-014-3653-8","article-title":"mGluR5 positive allosteric modulation and its effects on MK-801 induced set-shifting impairments in a rat operant delayed matching\/non-matching-to-sample task","volume":"232","author":"LaCrosse","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib84","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbr.2014.03.008","article-title":"mGluR3 knockout mice show a working memory defect and an enhanced response to MK-801 in the T- and Y-maze cognitive tests","volume":"266","author":"Lainiola","year":"2014","journal-title":"Behav Brain Res"},{"key":"10.1124\/molpharm.121.000460_bib85","article-title":"Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813","volume":"3","author":"Lavreysen","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/molpharm.121.000460_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fnmol.2019.00185","article-title":"NMDAR hypofunction animal models of schizophrenia","volume":"12","author":"Lee","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib87","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: past, present and future","volume":"16","author":"Li","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/molpharm.121.000460_bib88","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.euroneuro.2015.05.004","article-title":"Significant association of GRM7 and GRM8 genes with schizophrenia and major depressive disorder in the Han Chinese population","volume":"26","author":"Li","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1124\/molpharm.121.000460_bib89","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","article-title":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: a proof of principle study","volume":"172","author":"Litman","year":"2016","journal-title":"Schizophr Res"},{"key":"10.1124\/molpharm.121.000460_bib90","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/jpet.108.136580","article-title":"ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities","volume":"327","author":"Liu","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109950","article-title":"mGlu1 potentiation enhances prelimbic somatostatin interneuron activity to rescue schizophrenia-like physiological and cognitive deficits","volume":"37","author":"Maksymetz","year":"2021","journal-title":"Cell Rep"},{"key":"10.1124\/molpharm.121.000460_bib92","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1523\/JNEUROSCI.21-16-05925.2001","article-title":"Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function","volume":"21","author":"Mannaioni","year":"2001","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0306-4522(01)00199-3","article-title":"A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex","volume":"105","author":"Marek","year":"2001","journal-title":"Neuroscience"},{"key":"10.1124\/molpharm.121.000460_bib94","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0022-3565(24)35262-0","article-title":"Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex","volume":"292","author":"Marek","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib95","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1523\/JNEUROSCI.19-03-00955.1999","article-title":"Metabotropic glutamate receptor subtype 7 ablation causes deficit in fear response and conditioned taste aversion","volume":"19","author":"Masugi","year":"1999","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib96","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11682-017-9712-0","article-title":"Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia","volume":"12","author":"Matosin","year":"2018","journal-title":"Brain Imaging Behav"},{"key":"10.1124\/molpharm.121.000460_bib97","doi-asserted-by":"crossref","first-page":"18712","DOI":"10.1073\/pnas.0508063102","article-title":"A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo","volume":"102","author":"Mitsukawa","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.121.000460_bib98","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"key":"10.1124\/molpharm.121.000460_bib99","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.121.000460_bib100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0092-8674(00)81972-8","article-title":"Mice with reduced NMDA receptor expression display behaviors related to schizophrenia","volume":"98","author":"Mohn","year":"1999","journal-title":"Cell"},{"key":"10.1124\/molpharm.121.000460_bib101","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nlm.2019.01.006","article-title":"A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition","volume":"158","author":"Neale","year":"2019","journal-title":"Neurobiol Learn Mem"},{"key":"10.1124\/molpharm.121.000460_bib102","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/molpharm.121.000460_bib103","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neulet.2015.07.047","article-title":"Association study of GRM7 polymorphisms and schizophrenia in the Chinese Han population","volume":"604","author":"Niu","year":"2015","journal-title":"Neurosci Lett"},{"key":"10.1124\/molpharm.121.000460_bib104","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1124\/mol.111.075184","article-title":"Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function","volume":"81","author":"Noetzel","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib105","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1038\/s41598-018-22768-x","article-title":"Physiological activation of mGlu5 receptors supports the ion channel function of NMDA receptors in hippocampal LTD induction in vivo","volume":"8","author":"O\u2019Riordan","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/molpharm.121.000460_bib106","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1471-4159.2004.02358.x","article-title":"NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR","volume":"89","author":"Olszewski","year":"2004","journal-title":"J Neurochem"},{"key":"10.1124\/molpharm.121.000460_bib107","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.schres.2012.01.007","article-title":"mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia","volume":"136","author":"Olszewski","year":"2012","journal-title":"Schizophr Res"},{"key":"10.1124\/molpharm.121.000460_bib108","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1038\/tp.2012.68","article-title":"NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia","volume":"2","author":"Olszewski","year":"2012","journal-title":"Transl Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib109","first-page":"295","article-title":"Potential antipsychotic and extrapyramidal effects of (R,S)-3,4-dicarboxyphenylglycine [(R,S)-3,4-DCPG], a mixed AMPA antagonist\/mGluR8 agonist","volume":"56","author":"Ossowska","year":"2004","journal-title":"Pol J Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib110","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.neuropharm.2008.06.033","article-title":"Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents","volume":"55","author":"Pa\u0142ucha-Poniewiera","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.121.000460_bib111","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neuropharm.2012.12.003","article-title":"Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target","volume":"82","author":"Parmentier-Batteur","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.121.000460_bib112","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat Med"},{"key":"10.1124\/molpharm.121.000460_bib113","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Per\u00e4l\u00e4","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib114","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/hmg\/ddw007","article-title":"Comprehensive analysis of schizophrenia-associated loci highlights ion channel pathways and biologically plausible candidate causal genes","volume":"25","author":"Pers","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1124\/molpharm.121.000460_bib115","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.neuron.2015.04.022","article-title":"Novel findings from CNVs implicate inhibitory and excitatory signaling complexes in schizophrenia","volume":"86","author":"Pocklington","year":"2015","journal-title":"Neuron"},{"key":"10.1124\/molpharm.121.000460_bib116","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1073\/pnas.1815129116","article-title":"Effective connectivity changes in LSD-induced altered states of consciousness in humans","volume":"116","author":"Preller","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.121.000460_bib117","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/hbm.24976","article-title":"mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia","volume":"41","author":"R\u00e9gio Brambilla","year":"2020","journal-title":"Hum Brain Mapp"},{"key":"10.1124\/molpharm.121.000460_bib118","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1124\/mol.110.067207","article-title":"Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity","volume":"78","author":"Rodriguez","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib119","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.biopsych.2012.09.012","article-title":"Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity","volume":"73","author":"Rook","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib120","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.neuron.2015.03.063","article-title":"Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents","volume":"86","author":"Rook","year":"2015","journal-title":"Neuron"},{"key":"10.1124\/molpharm.121.000460_bib121","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-007-0758-3","article-title":"In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2\/3 receptor agonist LY404039 in animal models of psychiatric disorders","volume":"193","author":"Rorick-Kehn","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib122","doi-asserted-by":"crossref","first-page":"e1196","DOI":"10.1038\/tp.2017.172","article-title":"Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk","volume":"7","author":"Saini","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib123","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0269881115573403","article-title":"Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies","volume":"29","author":"Salih","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1124\/molpharm.121.000460_bib124","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.biopsych.2010.10.030","article-title":"Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine","volume":"69","author":"Santana","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib125","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.108.138107","volume":"326","author":"Satow","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib126","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1124\/jpet.109.151118","article-title":"Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one","volume":"330","author":"Satow","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib127","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1124\/molpharm.121.000460_bib128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pbb.2009.12.002","article-title":"Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia","volume":"95","author":"Schlumberger","year":"2010","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/molpharm.121.000460_bib129","doi-asserted-by":"crossref","first-page":"8846","DOI":"10.1523\/JNEUROSCI.20-23-08846.2000","article-title":"DOI-Induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons","volume":"20","author":"Scruggs","year":"2000","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib130","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/bph.12254","article-title":"The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents","volume":"169","author":"S\u0142awi\u0144ska","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib131","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(00)00269-7","article-title":"Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice","volume":"397","author":"Spooren","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib132","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0092-8674(00)80921-6","article-title":"Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo","volume":"92","author":"Sprengel","year":"1998","journal-title":"Cell"},{"key":"10.1124\/molpharm.121.000460_bib133","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1092852918001013","article-title":"Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate","volume":"23","author":"Stahl","year":"2018","journal-title":"CNS Spectr"},{"key":"10.1124\/molpharm.121.000460_bib134","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","article-title":"Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo","volume":"150","author":"Stauffer","year":"2013","journal-title":"Schizophr Res"},{"key":"10.1124\/molpharm.121.000460_bib135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2010.01.028","article-title":"Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade","volume":"639","author":"Stefani","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib136","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/jpet.113.211185","article-title":"mGluR5 antagonist-induced psychoactive properties: MTEP drug discrimination, a pharmacologically selective non-NMDA effect with apparent lack of reinforcing properties","volume":"349","author":"Swedberg","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/molpharm.121.000460_bib137","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0024-3205(03)00509-5","article-title":"Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat","volume":"73","author":"Takamori","year":"2003","journal-title":"Life Sci"},{"key":"10.1124\/molpharm.121.000460_bib138","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamapsychiatry.2013.1195","article-title":"Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families","volume":"70","author":"Timms","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib139","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.neuropharm.2009.07.022","article-title":"Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus","volume":"57","author":"Uslaner","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.121.000460_bib140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2009.11.067","article-title":"The difference in effect of mGlu2\/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801","volume":"639","author":"Vales","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib141","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.neuron.2008.09.039","article-title":"Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks","volume":"60","author":"von Engelhardt","year":"2008","journal-title":"Neuron"},{"key":"10.1124\/molpharm.121.000460_bib142","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1073\/pnas.1416196112","article-title":"Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction","volume":"112","author":"Walker","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/molpharm.121.000460_bib143","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41380-018-0234-y","article-title":"mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia","volume":"25","author":"Wang","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib144","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1111\/bcp.14331","article-title":"Safety and pharmacokinetic profiles of MGS0274 besylate (TS-134), a novel metabotropic glutamate 2\/3 receptor agonist prodrug, in healthy subjects","volume":"86","author":"Watanabe","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/molpharm.121.000460_bib145","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-014-3657-4","article-title":"The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies","volume":"232","author":"Wiero\u0144ska","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib146","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00213-011-2502-2","article-title":"Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia","volume":"220","author":"Wiero\u0144ska","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib147","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00213-007-0974-x","article-title":"The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2\/3 agonist, LY379268, in mouse models predictive of antipsychotic activity","volume":"196","author":"Woolley","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/molpharm.121.000460_bib148","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/1570159X13666150516000630","article-title":"Involvement of GABAB receptor signaling in antipsychotic-like action of the novel orthosteric agonist of the mGlu4 receptor, LSP4-2022","volume":"14","author":"Wo\u017aniak","year":"2016","journal-title":"Curr Neuropharmacol"},{"key":"10.1124\/molpharm.121.000460_bib149","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neuropharm.2016.06.025","article-title":"Neurochemical and behavioral studies on the 5-HT1A-dependent antipsychotic action of the mGlu4 receptor agonist LSP4-2022","volume":"115","author":"Wo\u017aniak","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1124\/molpharm.121.000460_bib150","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1471-4159.1997.69010174.x","article-title":"N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells","volume":"69","author":"Wroblewska","year":"1997","journal-title":"J Neurochem"},{"key":"10.1124\/molpharm.121.000460_bib151","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abd2319","article-title":"Input-specific regulation of glutamatergic synaptic transmission in the medial prefrontal cortex by mGlu2\/mGlu4 receptor heterodimers","volume":"14","author":"Xiang","year":"2021","journal-title":"Sci Signal"},{"key":"10.1124\/molpharm.121.000460_bib152","doi-asserted-by":"crossref","first-page":"16762","DOI":"10.1523\/JNEUROSCI.2869-13.2014","article-title":"Hippocampal metaplasticity is required for the formation of temporal associative memories","volume":"34","author":"Xu","year":"2014","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib153","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/acsmedchemlett.5b00450","article-title":"Discovery and preclinical evaluation of BMS-955829, a potent positive allosteric modulator of mGluR5","volume":"7","author":"Yang","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/molpharm.121.000460_bib154","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1523\/JNEUROSCI.1129-13.2014","article-title":"Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS","volume":"34","author":"Yin","year":"2014","journal-title":"J Neurosci"},{"key":"10.1124\/molpharm.121.000460_bib155","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/s41380-018-0206-2","article-title":"Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators","volume":"25","author":"Yohn","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1124\/molpharm.121.000460_bib156","doi-asserted-by":"crossref","first-page":"16412","DOI":"10.1038\/s41598-018-33929-3","article-title":"Touchscreen testing reveals clinically relevant cognitive abnormalities in a mouse model of schizophrenia lacking metabotropic glutamate receptor 5","volume":"8","author":"Zeleznikow-Johnston","year":"2018","journal-title":"Sci Rep"},{"key":"10.1124\/molpharm.121.000460_bib157","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.npp.1300013","article-title":"Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex","volume":"28","author":"Zhai","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/molpharm.121.000460_bib158","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1152\/jn.00072.2012","article-title":"NMDAR antagonist action in thalamus imposes \u03b4 oscillations on the hippocampus","volume":"107","author":"Zhang","year":"2012","journal-title":"J Neurophysiol"},{"key":"10.1124\/molpharm.121.000460_bib159","doi-asserted-by":"crossref","first-page":"21773","DOI":"10.1074\/jbc.M112.363226","article-title":"Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia","volume":"287","author":"Zuo","year":"2012","journal-title":"J Biol Chem"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24012276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24012276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/molpharm.121.000460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:50:17Z","timestamp":1739955017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24012276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":159,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0026895X24012276"],"URL":"https:\/\/doi.org\/10.1124\/molpharm.121.000460","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/molpharm.121.000460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}